Cyclarity Therapeutics

07/14/2025

Very nice commentary published by oxidized cholesterol expert Professor Gerard Lizard at the University of Burgundy on our recent paper in Atherosclerosis.

07/01/2025

Cyclarity's Dr. O'Connor on the Kill or Cure Podcast with Bill Liao and Todd Perman!

In this conversation, Todd Perman and Bill Liao engage with Matthew "Oki" O'Connor, CEO of Cyclarity Therapeutics, discussing the challenges and innovations ...

05/19/2025

Dr. O'Connor is featured on this week's meeting of the eRotary Club of Silicon Valley

MEETING FOR THE WEEK OF May 19, 2025 This Meeting at a Glance: Program: Cyclarity Therapeutics: Revolutionizing Age-Related Disease Treatment through Unique Drug Design Speaker: Dr. Matthew O'Connor Is this your first time visiting us?  If so, welcome to our weekly online meeting

03/19/2025

Very nice story about Cyclarity's journey and our 1st drug in clinical trials now!

You think you don’t know someone with atherosclerosis, but it’s likely you actually do. Atherosclerosis is the build-up of oxidized cholesterol in arteries, an underlying factor in an astonishing 50% of deaths in Western society. An indicator of dementia, Alzheimer’s, heart disease, lung disea...

02/11/2025

https://bakarlabs.berkeley.edu/cyclarity-therapeutics-secures-approval-for-first-in-human-clinical-trial/

Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX, one of Australia’s leading clinical research centers, in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Vic...

01/19/2025

Nice coverage of our clinical trial launch by Lifespan.io news. https://www.lifespan.io/news/cyclarity-launches-human-trial-for-atherosclerosis/?fbclid=IwY2xjawH6E4lleHRuA2FlbQIxMQABHbi8SukVNm7ACgW2OhDpy608wxod2JNiP-7LcGk2SzNrSGKIrmIJyJquWA_aem_AmqpvM6u8Gp027B5RN3FMg

Cyclarity Therapeutics, a biotechnology company based at the Buck Institute in California, has launched its first human clinical trial. Its primary candidate cyclodextrin drug, UDP-003, focuses on 7-ketocholesterol, an oxidized cholesterol […]

01/07/2025

Cyclarity's first drug going into humans! Healthy volunteers first and patients with atherosclerosis later this year.

NOVATO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical...

12/02/2024

Great story on philanthropist / investor and Cyclarity supporter James Fickel: https://www.bloomberg.com/news/articles/2024-11-11/crypto-millionaire-fuels-push-to-transform-brain-research?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTczMTMzNTIwMCwiZXhwIjoxNzMxOTQwMDAwLCJhcnRpY2xlSWQiOiJTTVNDMEtEV1gyUFMwMCIsImJjb25uZWN0SWQiOiI5MTM4NzMzNDcyQkY0QjlGQTg0OTI3QTVBRjY1QzBCRiJ9.UIiE3EaM5HQ5UfwHj9PsTI2J6PuCfQ0bPhFvv7XsmU8&sref=nPlhheXZ&leadSource=uverify%20wall&embedded-checkout=true

James Fickel has dedicated $200 million he made betting on Ether to becoming one of the world’s biggest investors in those fields.

10/22/2024

New interview with our Co-CEO Matthew O'Connor on the LongeCity podcast!

Pioneers in life extension research & advocacy interviewed by the Longecity.org community forum.

07/24/2024

Exciting News! 🎉

We at Cyclarity are thrilled to announce that we have officially submitted our trial application to the Human Research Ethics Committees (HREC) in Australia for our First in Human clinical trial!

This milestone marks our transition to a clinical-stage company, and we couldn’t be more proud of our hardworking team in California. 🙌

Our upcoming clinical trial will be conducted at CMAX in Adelaide, partnered with Monash University under the esteemed guidance of Dr. Stephen Nicholls, a world-renowned cardiologist and leader at the Victorian Heart Institute (VHI).

Stay tuned for more updates as we embark on this exciting journey towards groundbreaking advancements in healthcare!

07/23/2024

Dr. O'Connor speaking at Longevity Summit Dublin in June. Take a look!

05/25/2024

Dr. Daniel M. Clemens, our V.P. of Biology, will be presenting at the 2024 European Atherosclerosis Society Congress in Lyon on Tuesday, May 28. Daniel will be presenting new and exciting data about the efficacy and clinical readiness of UDP-003, our intended first-in-class therapeutic for the reversal of atherosclerosis.

Come by the Science at a Glance presentation, or contact Daniel directly to setup a meeting. https://eas-congress.com/2024/

To contact Daniel: https://www.linkedin.com/in/dmclemens/

Visit https://cyclaritytx.com to learn more about our revolutionary approach to curing heart disease.